Furiex Pharmaceuticals (NASDAQ:FURX) has secured $15 million to finance R&D for three compounds in its drug pipeline.
The Morrisville, North Carolina drug development company has entered into a loan agreement with MidCap Financial and Silicon Valley Bank (NASDAQ:SIVB). Furiex has already received the first tranche, $10 million. The second tranche of $5 million will only become available if a “pre-defined Furiex financing event occurs.” No additional details on that financing event were disclosed.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Furiex was spun off of clinical research organization PPD (NYSE:PPDI) in 2010. As the compound partnering division of PPD, the unit developed the drug candidates discovered by PPD’s pharmaceutical partners. Furiex will direct the $15 million loan to the following three compounds, all of which are licensed from or are being developed with a partner:
JNJ-Q2. Furiex licensed this antibiotic compound from Janssen Pharmaceutica in April. JNJ-Q2 is being developed to address antibiotic-resistant strains such as Methicillin-resistant Staphylococcus aureus, or MRSA. JNJ-Q2 has completed phase 2 studies and the company has said it is exploring partnerships to take the compound into phase 3 clinical trials.
MuDelta. This compound is being developed to treat diarrhea-predominant irritable bowel syndrome. Furiex has a development and license agreement with Janssen, which gives Janssen the right to continue development and commercialization of MuDelta after Furiex completes phase 2 clinical trials. MuDelta is still in phase 2 studies.
PPD10558. Furiex licensed PPD10558, a cholesterol-lowering statin drug candidate, from Ranbaxy Laboratories. Furiex is studying the compound as a safer statin with fewer side effects. Other statins can be toxic to muscles throughout the body. Furiex has said that PPD10558 offers targeted delivery to the liver, minimizing muscle-related side effects. The compound is currently in phase 2 studies.